Obesity
Conditions
Brief summary
Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. The effects of intraduodenal and/or intraileal infusion of a combination of tastants (sweet (rebaudioside A), bitter (quinine) en umami (monosodium glutamate(MSG))) and placebo on ad libitum food intake, satiation and gastrointestinal symptoms will be investigated. Objective: To investigate the effect of intraduodenal, intraileal and combined infusion of a combination of tastants versus infusion of placebo on food intake. Secondary objectives: 1. To compare the effect of intraduodenal versus intraileal versus combined intraduodenal and intraileal delivery of a combination of tastants on satiation. 2. To assess the effect of intraduodenal and/or intraileal delivery of a combination of tastants on gastrointestinal symptoms/complaints.
Interventions
DIETARY_SUPPLEMENTTastants duodenal
Duodenal infusion of combination of tastants (sweet, bitter and umami)
DIETARY_SUPPLEMENTTastants ileal
Ileal infusion of combination of tastants (sweet, bitter and umami)
DIETARY_SUPPLEMENTPlacebo duodenal
Duodenal infusion of placebo (tap water)
DIETARY_SUPPLEMENTPlacebo ileal
Ileal infusion of placebo (tap water)
Sponsors
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Based on medical history and previous examination, no gastrointestinal complaints can be defined. * Age between 18 and 65 years. This study will include healthy adult subjects (male and female). Women must be taking contraceptives. * BMI between 18 and 25 kg/m2) * Weight stable over at least the last 6 months
Exclusion criteria
* History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator. * Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing * Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study * Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator) * Dieting (medically prescribed, vegetarian, diabetic, microbiological, biological dynamic) * Pregnancy, lactation * Excessive alcohol consumption (\>20 alcoholic consumptions per week) * Smoking * Weight \<60kg * Non-tasters of sweet, bitter or umami * Evidence of MSG-hypersensitivity or Chinese restaurant syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ad libitum meal intake | 5 weeks | Difference in ad libitum meal intake (as measured during ad libitum pasta meal) at end of the test day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Satiation | 5 weeks | Difference in satiation (as measured by VAS) per time point. |
| GI-symptoms | 5 weeks | Difference in gastro-intestinal symptoms (as measured by VAS) per time point. |
Countries
Netherlands
Outcome results
None listed